A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.
The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Final Accrual
60
Trial Chairperson
Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC
Clinical Trial Registration
Related Post
24 June, 2025
TROG 2024 Annual Research Report highlights a year of achievements
LATEST NEWS: 24 JUNE 2025 The latest annual report
11 June, 2025
Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer
LATEST NEWS: 11 JUNE 2025 New findings from a
